Loading...

FIT Biotech Oy

HLSE:FITBIO
Snowflake Description

Weak fundamentals or lack of information.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
FITBIO
HLSE
€743K
Market Cap
  1. Home
  2. FI
  3. Pharmaceuticals & Biotech
Company description

FIT Biotech Oy operates as a clinical-stage biotech company. The last earnings update was 186 days ago. More info.


Add to Portfolio Compare Print
  • FIT Biotech Oy has significant price volatility in the past 3 months.
FITBIO Share Price and Events
7 Day Returns
0%
HLSE:FITBIO
-1%
Europe Biotechs
-1.6%
FI Market
1 Year Returns
-83.3%
HLSE:FITBIO
9.1%
Europe Biotechs
-1.2%
FI Market
FITBIO Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
FIT Biotech Oy (FITBIO) 0% -50% -66.7% -83.3% -100% -
Europe Biotechs -1% 3.9% 3.5% 9.1% 19.5% 43.4%
FI Market -1.6% 0.5% 11.3% -1.2% 22.6% 37.3%
1 Year Return vs Industry and Market
  • FITBIO underperformed the Biotechs industry which returned 9.1% over the past year.
  • FITBIO underperformed the Market in Finland which returned -1.2% over the past year.
Price Volatility
FITBIO
Industry
5yr Volatility vs Market

FITBIO Value

 Is FIT Biotech Oy undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether FIT Biotech Oy is trading at an attractive price based on the cash flow it is expected to produce in the future. But as FIT Biotech Oy has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for FIT Biotech Oy. This is due to cash flow or dividend data being unavailable. The share price is €0.0002.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for FIT Biotech Oy's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are FIT Biotech Oy's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
HLSE:FITBIO PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.01
HLSE:FITBIO Share Price ** HLSE (2019-02-22) in EUR €0
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 22.18x
Finland Market PE Ratio Median Figure of 108 Publicly-Listed Companies 17.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of FIT Biotech Oy.

HLSE:FITBIO PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= HLSE:FITBIO Share Price ÷ EPS (both in EUR)

= 0 ÷ -0.01

-0.03x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FIT Biotech Oy is loss making, we can't compare its value to the Europe Biotechs industry average.
  • FIT Biotech Oy is loss making, we can't compare the value of its earnings to the Finland market.
Price based on expected Growth
Does FIT Biotech Oy's expected growth come at a high price?
Raw Data
HLSE:FITBIO PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.03x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 18 Publicly-Listed Biotechs Companies 1.29x
Finland Market PEG Ratio Median Figure of 91 Publicly-Listed Companies 1.67x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for FIT Biotech Oy, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on FIT Biotech Oy's assets?
Raw Data
HLSE:FITBIO PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €-0.01
HLSE:FITBIO Share Price * HLSE (2019-02-22) in EUR €0
Europe Biotechs Industry PB Ratio Median Figure of 161 Publicly-Listed Biotechs Companies 2.87x
Finland Market PB Ratio Median Figure of 140 Publicly-Listed Companies 2.06x
HLSE:FITBIO PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= HLSE:FITBIO Share Price ÷ Book Value per Share (both in EUR)

= 0 ÷ -0.01

-0.03x

* Primary Listing of FIT Biotech Oy.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • FIT Biotech Oy has negative assets, we can't compare the value of its assets to the Europe Biotechs industry average.

Next steps:

  1. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through FIT Biotech Oy's regulatory filings and announcements.
  2. Show me more potentially undervalued companies in the Biotechs industry
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess FIT Biotech Oy's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. FIT Biotech Oy has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

FITBIO Future Performance

 How is FIT Biotech Oy expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as FIT Biotech Oy has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
14.2%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is FIT Biotech Oy expected to grow at an attractive rate?
  • Unable to compare FIT Biotech Oy's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare FIT Biotech Oy's earnings growth to the Finland market average as no estimate data is available.
  • Unable to compare FIT Biotech Oy's revenue growth to the Finland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
HLSE:FITBIO Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 14.2%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 12.6%
Finland Market Earnings Growth Rate Market Cap Weighted Average 15.5%
Finland Market Revenue Growth Rate Market Cap Weighted Average 0.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
HLSE:FITBIO Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
HLSE:FITBIO Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 0 -3 -4
2018-03-31 0 -3 -4
2017-12-31 1 -3 -3
2017-09-30 1 -3 -3
2017-06-30 1 -3 -4
2017-03-31 0 -3 -4
2016-12-31 0 -2 -4
2016-09-30 0 -3 -3
2016-06-30 0 -3 -3
2016-03-31 0 -3 2
2015-12-31 0 -2 3
2015-09-30 0 -2 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if FIT Biotech Oy is high growth as no earnings estimate data is available.
  • Unable to determine if FIT Biotech Oy is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
HLSE:FITBIO Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (8 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from FIT Biotech Oy Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HLSE:FITBIO Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.05
2017-09-30 -0.07
2017-06-30 -0.09
2017-03-31 -0.11
2016-12-31 -0.13
2016-09-30 -0.10
2016-06-30 -0.11
2016-03-31 0.08
2015-12-31 0.09
2015-09-30 0.11

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if FIT Biotech Oy will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. FIT Biotech Oy's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. FIT Biotech Oy's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess FIT Biotech Oy's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
FIT Biotech Oy has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

FITBIO Past Performance

  How has FIT Biotech Oy performed over the past 5 years?

  • FIT Biotech Oy's last earnings update was 186 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare FIT Biotech Oy's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • FIT Biotech Oy does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare FIT Biotech Oy's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare FIT Biotech Oy's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
FIT Biotech Oy's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from FIT Biotech Oy Company Filings, last reported 8 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

HLSE:FITBIO Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 0.35 -3.75 1.01
2018-03-31 0.47 -3.53 1.03
2017-12-31 0.60 -3.30 1.05
2017-09-30 0.57 -3.43 1.11
2017-06-30 0.54 -3.56 1.18
2017-03-31 0.37 -3.60 1.09
2016-12-31 0.20 -3.65 0.99
2016-09-30 0.13 -3.34 0.93
2016-06-30 0.06 -3.02 0.87
2016-03-31 0.00 2.15 0.97
2015-12-31 0.07 2.62 0.88
2015-09-30 0.15 3.12 0.82
2015-06-30 0.22 3.62 0.77
2015-03-31 0.28 -1.19 0.57
2014-12-31 0.24 -2.30 0.53
2013-12-31 0.63 -2.59 0.57
2012-12-31 -2.16 0.64

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if FIT Biotech Oy has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if FIT Biotech Oy has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if FIT Biotech Oy improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess FIT Biotech Oy's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
FIT Biotech Oy has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

FITBIO Health

 How is FIT Biotech Oy's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up FIT Biotech Oy's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • FIT Biotech Oy's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • FIT Biotech Oy's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of FIT Biotech Oy's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • FIT Biotech Oy has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from FIT Biotech Oy Company Filings, last reported 8 months ago.

HLSE:FITBIO Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 -13.12 13.52 0.03
2018-03-31 -13.12 13.52 0.03
2017-12-31 -13.32 13.56 0.43
2017-09-30 -13.32 13.56 0.43
2017-06-30 -12.61 12.87 0.02
2017-03-31 -12.61 12.87 0.02
2016-12-31 -12.40 13.04 0.49
2016-09-30 -12.40 13.04 0.49
2016-06-30 -10.75 11.77 0.52
2016-03-31 -10.75 11.77 0.52
2015-12-31 -9.27 11.77 1.84
2015-09-30 -9.27 11.77 1.84
2015-06-30 -7.73 11.77 3.40
2015-03-31 -21.62 22.94 0.65
2014-12-31 -21.35 22.25 0.22
2013-12-31 -20.32 21.90 0.12
2012-12-31 -17.73 20.48 0.30
  • FIT Biotech Oy has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if FIT Biotech Oy's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • FIT Biotech Oy has less than a year of cash runway based on current free cash flow.
  • FIT Biotech Oy has less than a year of cash runway if free cash flow continues to grow at historical rates of 5.7% each year.
X
Financial health checks
We assess FIT Biotech Oy's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. FIT Biotech Oy has a total score of 0/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

FITBIO Dividends

 What is FIT Biotech Oy's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from FIT Biotech Oy dividends.
If you bought €2,000 of FIT Biotech Oy shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate FIT Biotech Oy's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate FIT Biotech Oy's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
HLSE:FITBIO Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 0.9%
Finland Market Average Dividend Yield Market Cap Weighted Average of 102 Stocks 4.3%
Finland Minimum Threshold Dividend Yield 10th Percentile 1.6%
Finland Bottom 25% Dividend Yield 25th Percentile 2.3%
Finland Top 25% Dividend Yield 75th Percentile 5.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as FIT Biotech Oy has not reported any payouts.
  • Unable to verify if FIT Biotech Oy's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of FIT Biotech Oy's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as FIT Biotech Oy has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess FIT Biotech Oy's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.6%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can FIT Biotech Oy afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. FIT Biotech Oy has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

FITBIO Management

 What is the CEO of FIT Biotech Oy's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Erkki Pekkarinen
TENURE AS CEO 1.2 years
CEO Bio

Mr. Erkki Pekkarinen has been Chief Executive Officer of FIT Biotech Oy since January 2018. Mr. Pekkarinen is the Partner and Chairman of Bio Fund Management Ltd. Mr. Pekkarinen is an Owner of BioFund. Mr. Pekkarinen has worked in BioFund since December 1999 and served as its President for ten years. He has worked lengthy periods in senior positions as institutional investor and financial advisor in private and public organizations. Along with his normal duties, he is in charge of fund formation and investor relations and is actively participating in the board work in BioFund's portfolio companies. Mr. Pekkarinen served a variety of managerial positions in investment activities and financial administration, the last one being that of Director of Finance at the Local Government Pensions Institution. He has also worked in unicipal finances and funding, conducted diversified business-related research and taught at the Helsinki School of Economics and Business Administration. In addition, he has worked extensively in consulting, for example as a Restructuring Consultant. He was a Director of FIT Biotech Oy since 2002 until January 2018. He served as Non Executive Director of Aplagon Oy. He served as a Director of Suomen pääomasijoitusyhdistys ry. He is an Advisor in corporate financial arrangements, Placement Agent and Professional Board Member. He has a M.B.A. in 1982 from the Helsinki School of Economics and Business Administration.

CEO Compensation
  • Insufficient data for Erkki to compare compensation growth.
  • Insufficient data for Erkki to establish whether their remuneration is reasonable compared to companies of similar size in Finland.
Management Team Tenure

Average tenure and age of the FIT Biotech Oy management team in years:

1.2
Average Tenure
51
Average Age
  • The average tenure for the FIT Biotech Oy management team is less than 2 years, this suggests a new team.
Management Team

Erkki Pekkarinen

TITLE
Chief Executive Officer
TENURE
1.2 yrs

Tommi Holopainen

TITLE
Chief Financial Officer
TENURE
0.6 yrs

Santeri Kiviluoto

TITLE
VP & Chief Scientific Officer
AGE
36
TENURE
1.8 yrs

Matti Lähde

TITLE
Chief Production Officer
AGE
61

Jussi Seitsonen

TITLE
Chief Quality Officer
AGE
51
Board of Directors Tenure

Average tenure and age of the FIT Biotech Oy board of directors in years:

2.2
Average Tenure
64.5
Average Age
  • The average tenure for the FIT Biotech Oy board of directors is less than 3 years, this suggests a new board.
Board of Directors

Rabbe Slätis

TITLE
Director
AGE
71
TENURE
18.2 yrs

Richard Koup

TITLE
Member of Scientific Advisory Board

Giuseppe Pantaleo

TITLE
Member of Scientific Advisory Board

Roger Le Grand

TITLE
Member of Scientific Advisory Board

Stanley Plotkin

TITLE
Member of Scientific Advisory Board
AGE
85

Michael Lederman

TITLE
Member of Scientific Advisory Board

Eero Rautalahti

TITLE
Director
AGE
58
TENURE
2.2 yrs

Anne-Maria Salonius

TITLE
Director
AGE
54
TENURE
1.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess FIT Biotech Oy's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. FIT Biotech Oy has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

FITBIO News

Simply Wall St News

Does FIT Biotech Oy (HEL:FITBIO) Fall With The Market?

Generally, an investor should consider two types of risk that impact the market value of FITBIO. … The first type is company-specific risk, which can be diversified away by investing in other companies to reduce exposure to one particular stock. … The second type is market risk, one that you cannot diversify away, since it arises from macroeconomic factors which directly affects all the stocks in the market.

Simply Wall St -

Who Owns Most Of FIT Biotech Oy (HEL:FITBIO)?

In this analysis, my focus will be on developing a perspective on FIT Biotech Oy’s (HLSE:FITBIO) latest ownership structure, a less discussed, but important factor. … Insider Ownership Another important group of shareholders are company insiders. … With this size of ownership, retail investors can collectively play a role in major company policies that affect shareholders returns, including executive remuneration and the appointment of directors.

Simply Wall St -

FIT Biotech Oy (HEL:FITBIO): Risks You Need To Consider Before Buying

I test FITBIO’s ratio of fixed assets to total assets in order to determine how high the risk is associated with this type of constraint. … Thus, we can expect FITBIO to be more stable in the face of market movements, relative to its peers of similar size but with a higher portion of fixed assets on their books. … However, this is the opposite to what FITBIO’s actual beta value suggests, which is higher stock volatility relative to the market.

Simply Wall St -

Interested In FIT Biotech Oy (HEL:FITBIO)? Here's How It Performed Recently

After looking at FIT Biotech Oy's (HLSE:FITBIO) latest earnings announcement (31 December 2017), I found it useful to revisit the company's performance in the past couple of years and assess this against the most recent figures. … View our latest analysis for FIT Biotech Oy Did FITBIO's recent earnings growth beat the long-term trend and the industry? … HLSE:FITBIO Income Statement Apr 25th 18 We can further examine FIT Biotech Oy's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

FITBIO Company Info

Map
Description

FIT Biotech Oy operates as a clinical-stage biotech company. The company focuses on developing antibody gene delivery technologies and gene vaccines for cancer immunotherapy, and the prevention and treatment of infectious diseases, such as HIV and tuberculosis, as well as animal vaccines. The company develops and licenses its patented gene transport unit (GTU) vector technology for new-generation medical treatments. It also markets FIT-06, a GTU-based DNA vaccine, for the treatment of HIV patients. It has a research collaboration agreement with Avacta Group plc to develop gene therapies. FIT Biotech Oy was founded in 1995 and is based in Tampere, Finland.

Details
Name: FIT Biotech Oy
FITBIO
Exchange: HLSE
Founded: 1995
€743,142
3,715,711,264
Website: http://www.fitbiotech.com
Address: FIT Biotech Oy
Biokatu 12,
Tampere,
Pirkanmaa, 33520,
Finland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
HLSE FITBIO Series K Shares OMX Nordic Exchange Helsinki FI EUR 01. Jul 2015
Number of employees
Current staff
Staff numbers
10
FIT Biotech Oy employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/03/11 21:45
End of day share price update: 2019/02/22 00:00
Last earnings filing: 2018/09/06
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.